Feature

Are Direct-to-Consumer Microbiome Tests Clinically Useful?


 

Educate Clinicians, Companies

More education is needed on the subject, so we can become “microbial clinicians,” Dr. Kao said.

“The microbiome never came up when I was going through my medical education,” she said. But we, and the next generation of physicians, “need to at least be able to understand the basics.

“Hopefully, one day, we will be in a position where we can have meaningful interpretations of the test results and make some kind of meaningful dietary interventions,” Dr. Kao added.

As for clinicians who are currently ordering these tests and products directly from the DTC companies, Dr. Kao said, “I roll my eyes.”

Dr. Ghannoum reiterated that companies offering microbiome tests and products also need to be educated and encouraged to use systematic approaches to product development and interpretation.

“Companies should be open to calls from clinicians and be ready to explain findings on a report, as well as the basis for any recommendations,” he said.

Dr. von Rosenvinge, Dr. Kao, and Dr. Kelly had no relevant conflicts of interest. Dr. Ghannoum is a cofounder of BIOHM.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

FDA OKs first ustekinumab biosimilar
MDedge Rheumatology
Review estimates acne risk with JAK inhibitor therapy
MDedge Rheumatology
TNF blockers not associated with poorer pregnancy outcomes
MDedge Rheumatology
Comorbidities and Disease Type Weigh Heavily in Pregnancy Outcomes of Immune-Mediated Inflammatory Diseases
MDedge Rheumatology
Autoimmune Disease Risk May Rise Following Cushing Disease Remission After Surgery
MDedge Rheumatology
FDA Approves 10th Humira Biosimilar, With Interchangeability
MDedge Rheumatology
How Good are Tools to Screen for Spondyloarthritis in Patients With Psoriasis, Uveitis, IBD?
MDedge Rheumatology
Top Spondyloarthritis Studies of 2023 Include Underdiagnosis and Treatment in IBD
MDedge Rheumatology
A 30-Year-Old White Female Presented With a 4-Month History of Scaly, Erythematous Patches and Plaques on Her Trunk and Extremities
MDedge Rheumatology
Second Ustekinumab Biosimilar Gets FDA Approval
MDedge Rheumatology